Amended Current Report Filing (8-k/a)
26 Gennaio 2017 - 3:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): January 26, 2016
(November 29, 2016)
Mymetics Corporation
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-25132
|
|
25-1741849
|
|
|
|
|
|
(State of other
jurisdiction)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
Route de la
Corniche 4
|
|
NA
|
1066 Epalinges,
Switzerland
|
|
(Zip
Code)
|
(Address of
principal executive
offices)
|
|
|
Registrant’s
telephone number, including area code: +011 41 21 653 45
35
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
[ ]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Explanatory
Note
On
December 1, 2016, Mymetics Corporation (“Mymetics”),
filed a current report on Form 8-K reporting the entry into a
material definitive agreement (the Research Agreement) under Item
1.01 with Sanofi Pasteur Biologics, LLC ("Sanofi"), the vaccine
division of Sanofi SA, and did not attach Appendix A, the
confidentiality agreement between Mymetics and Sanofi, to the
Research Agreement. This Amendment No. 1 on Form 8-K/A amends the
prior disclosure to include an unredacted Appendix A to the
redacted Research Agreement previously filed as Exhibit
10.1.
Item
9.01.
Financial
Statements and Exhibits
(d)
Exhibits.
10.1
Research Agreement
effective October 21, 2016 between Sanofi Biologics, LLC and
Mymetics BV*
99.1
Press Release dated
December 1, 2016
*Portions of this
exhibit 10.1 have been omitted and separately filed with the SEC
with a request for confidential treatment.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
MYMETICS
CORPORATION
|
|
|
|
|
|
Date:
January
25, 2017
|
By:
|
/s/
Ronald
Kempers
|
|
|
|
Ronald
Kempers
|
|
|
|
President and Chief
Executive Officer
|
|
Grafico Azioni Mymetics (CE) (USOTC:MYMX)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Mymetics (CE) (USOTC:MYMX)
Storico
Da Nov 2023 a Nov 2024